Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China.
Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2021 Mar 5;12:615913. doi: 10.3389/fendo.2021.615913. eCollection 2021.
Cathepsin S, as an adipokine, was reported to play a critical role in various disease, including atherosclerosis and diabetes. The present study aims to elucidate the relationship between circulating cathepsin S and cardiovascular disease (CVD) in patients with type 2 diabetes.
A total of 339 type 2 diabetes individuals were enrolled in this cross-sectional community-based study. Basic information, medical and laboratory data were collected. Serum cathepsin S levels were assessed by ELISA.
Compared to the CVD (-) group, levels of serum cathepsin S were significantly higher in the CVD (+) group, with the median 23.68 ng/ml (18.54-28.02) and 26.81 ng/ml (21.19-37.69) respectively ( < 0.001). Moreover, patients with acute coronary syndrome (ACS) had substantially higher levels of serum cathepsin S than those with stable angina pectoris (SAP), with the median 34.65 ng/ml (24.33-42.83) and 25.52 ng/ml (20.53-31.47) respectively ( < 0.01). The spearman correlation analysis showed that circulating cathepsin S was correlated with several cardiovascular risk factors. The univariate and multivariate logistic regression analysis revealed that circulating cathepsin S was an independent risk factor for CVD (all < 0.001) after adjustment for potential confounders. Restricted cubic spline analysis showed circulating cathepsin S had a linearity association with CVD. In addition, receiver operating characteristic (ROC) curve analysis demonstrated that the area under curve (AUC) values of cathepsin S was 0.80 (95% CI: 0.75-0.84, < 0.001), with the optimal cutoff value of cathepsin 26.28 ng/ml.
Circulating cathepsin S was significantly higher in the CVD (+) group than that in the CVD (-) one among type 2 diabetes. The increased serum cathepsin S levels were associated with increased risks of CVD, even after adjusting for potential confounders. Thus, cathepsin S might be a potential diagnostic biomarker for CVD.
组织蛋白酶 S 作为一种脂肪因子，在包括动脉粥样硬化和糖尿病在内的各种疾病中发挥着关键作用。本研究旨在阐明 2 型糖尿病患者循环组织蛋白酶 S 与心血管疾病（CVD）之间的关系。
本横断面社区研究共纳入 339 例 2 型糖尿病患者。收集基本信息、临床和实验室数据。采用 ELISA 法检测血清组织蛋白酶 S 水平。
与 CVD（-）组相比，CVD（+）组患者血清组织蛋白酶 S 水平显著升高，中位数分别为 23.68ng/ml（18.54-28.02）和 26.81ng/ml（21.19-37.69）（<0.001）。此外，急性冠脉综合征（ACS）患者血清组织蛋白酶 S 水平明显高于稳定型心绞痛（SAP）患者，中位数分别为 34.65ng/ml（24.33-42.83）和 25.52ng/ml（20.53-31.47）（<0.01）。Spearman 相关分析显示，循环组织蛋白酶 S 与多种心血管危险因素相关。单因素和多因素 logistic 回归分析显示，调整潜在混杂因素后，循环组织蛋白酶 S 是 CVD 的独立危险因素（均<0.001）。受限立方样条分析显示，循环组织蛋白酶 S 与 CVD 呈线性关系。此外，受试者工作特征（ROC）曲线分析显示，组织蛋白酶 S 的曲线下面积（AUC）值为 0.80（95%CI：0.75-0.84，<0.001），最佳截断值为 26.28ng/ml。
2 型糖尿病患者中，CVD（+）组血清组织蛋白酶 S 水平明显高于 CVD（-）组。即使在校正了潜在的混杂因素后，血清组织蛋白酶 S 水平的升高与 CVD 风险的增加相关。因此，组织蛋白酶 S 可能是 CVD 的潜在诊断生物标志物。
